Fresh analysis reveals that patients who come off new slimming jabs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise programs.
Findings released in a leading health publication demonstrates that while overweight individuals can lose about a fifth of their body weight while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month once they quit.
"Individuals purchasing such medications should be cognizant of the danger of rapid weight regain when the therapy is stopped," stated expert Dr. Susan Jebb.
Such speed of recovery implies a reversion to pre-treatment weight within about one and a half years.
Analyzing Approaches
The research, which examined dozens of trials involving thousands of participants, compared the effects of these new drugs with older methods.
Researchers emphasize that people who lose weight through lifestyle changes alone usually experience a less rapid weight regain—perhaps 0.1 kg a month—after stopping.
The Reason for the Rapid Regain
Experts suggest the mechanism of the injections accounts for the amplified weight return.
GLP-1 drugs imitate a natural hormone called GLP-1, which controls hunger.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production might result in the system to produce less of its endogenous hormone, and could reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this medication results in hunger is uncontrolled, making overeating far more likely."
A Chronic Disease?
Medical guidelines recommend the jabs for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts argue that, due to the likelihood of weight regain, the therapy should be considered ongoing.
This perspective is supported by drug manufacturers, who state that the findings "highlight the long-term nature of obesity," akin to managing conditions like diabetes.
User Testimonies
Users who have stopped the medication explain a intense resurgence of hunger.
"It felt as if something that goes on and you become starving," described one woman.
This difficulty is compounded if patients have not adopted lasting lifestyle or habit modifications during therapy.
Significant Interest
Survey data indicate that millions of people in the UK have tried these injections in the past year, with interest being substantial.
- Use is higher among females than males.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Ultimately, clinicians stress that while these medications are effective tools for shedding pounds, they are not a standalone fix and long-term success relies on ongoing lifestyle management.
